Unique ID issued by UMIN | UMIN000016606 |
---|---|
Receipt number | R000019271 |
Scientific Title | Efficacy and safety of electroporation and MTX combination therapy for the patients with RA |
Date of disclosure of the study information | 2015/04/01 |
Last modified on | 2019/02/19 08:32:00 |
Efficacy and safety of electroporation and MTX combination therapy for the patients with RA
Combination therapy of electroporation and MTX for the patients with RA
Efficacy and safety of electroporation and MTX combination therapy for the patients with RA
Combination therapy of electroporation and MTX for the patients with RA
Japan |
rheumatoid arthritis
Clinical immunology | Orthopedics |
Others
NO
To evaluate the efficacy and safety of electroporation using for drug delivery system for patients with rheumatoid arthritis.
Safety,Efficacy
Exploratory
Pragmatic
Phase II
Disease activity of local inflammation by Visual Analogue Scale (VAS)
1. Ultrasound assessment: Gray and power dopplar scale of local site.
2. Disease activity assessment: Mean value of DAS28, Mean change from baseline of DAS28.
3. Joint destruction: Change of modified Total Sharp Score (mTSS) from baseline.
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Placebo
Central registration
2
Treatment
Medicine | Device,equipment | Maneuver |
* Evaluate the articular synovitis by gray and power dopplar scale using ultrasound (US).
* Injection MTX (5mg/ml, 1ml) into MP or PIP joint using guide of US. After three minutes, perform electroporation for four angles with US gel.
* Condition of electroporation is 50V/cm 250ms 4puluse.
* Single intervention of injection MTX or combination of MTX and electroporation. Evaluation is performed at 2, 4, 12, and 26 weeks after baseline.
* Evaluate the articular synovitis by gray and power dopplar scale using ultrasound (US).
* Injection MTX (5mg/ml, 1ml) into MP or PIP joint using guide of US.
* Single intervention of injection MTX or combination of MTX and electroporation. Evaluation is performed at 2, 4, 12, and 26 weeks after baseline.
20 | years-old | <= |
Not applicable |
Male and Female
* Rheumatoid arthritis (RA)
* No limitation of duration of RA
* Patient who are recieving standard RA treatment
* Patient who are stable disease activity during three months by Methotrexate
* Patient who have swelling and tenderness at PIP or MP joint by positive power dopplar of ultrasound
* Patient who are stable disease activity during three months by Steroid or biologic agent
* Patient who had a history of hypersensitivity for Methotrexate
* Patient who have history of implantation and metallic material
* Patient who had a significant unstable RA disease status
* Patients who have infection disease
* Patient who was pregnant, planning on becoming pregnant or breast feeding Patient who had a history of seizures
60
1st name | |
Middle name | |
Last name | Kentaro Inui |
Osaka City University Medical School
Department of Orthopedic Surgery
Osaka
06-6645-3852
inuken@med.osaka-cu.ac.jp
1st name | |
Middle name | |
Last name | Kentaro Inui |
Osaka City University Medical School
Department of Orthopedic Surgery
Osaka
06-6645-3852
inuken@med.osaka-cu.ac.jp
Osaka City University Medical School, Department of Orthopedic Surgery
Grant-in-Aid for Scientific Research (C)
Japanese Governmental office
NO
2015 | Year | 04 | Month | 01 | Day |
Unpublished
Completed
2015 | Year | 03 | Month | 31 | Day |
2015 | Year | 04 | Month | 01 | Day |
2017 | Year | 12 | Month | 01 | Day |
2017 | Year | 12 | Month | 01 | Day |
2015 | Year | 02 | Month | 23 | Day |
2019 | Year | 02 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019271
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |